Propanc Biopharma Secures Strategic Financing to Enhance Clinical Development

According to PANews, Propanc Biopharma, a digital asset finance company, has announced a strategic financing agreement with family office Hexstone Capital, valued at up to $100 million. This funding aims to accelerate the development of the biopharmaceutical company's clinical pipeline and plans to increase the value of its digital asset portfolio to $100 million or more within the next 12 months. Hexstone Capital has previously invested in several companies with digital asset portfolios, including BTC, ETH, SOL, and DOGE.